# Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL)

> **NCT02192021** · PHASE1 · COMPLETED · sponsor: **Falo, Louis, MD** · enrollment: 20 (actual)

## Conditions studied

- Cutaneous T Cell Lymphoma

## Interventions

- **DRUG:** Micro needle array-Doxorubicin (MNA-D)

## Key facts

- **NCT ID:** NCT02192021
- **Lead sponsor:** Falo, Louis, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-09
- **Primary completion:** 2020-11-21
- **Final completion:** 2020-12-09
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2024-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02192021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02192021, "Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02192021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*